navigating biosimilars: extrapolation, naming, substitution (blue line)
Published 6 years ago • 54 plays • Length 8:03Download video MP4
Download video MP3
Similar videos
-
8:32
navigating biosimilars: implications for clinicians (red line)
-
0:50
navigating biosimilars: introduction
-
6:31
navigating biosimilars: patient education (green line)
-
3:39
navigating biosimilars: biologics landscape (orange line)
-
10:00
navigating biosimilars: biologics and biosimilars (gray line)
-
1:28:45
implantable bci technology - the road to access
-
54:43
closed caption version - wm basics diagnostics, understanding lab tests, symptoms
-
38:15
biosimilars and biologics
-
20:06
biologics and biosimilars: extrapolation of indications – information for healthcare providers
-
8:21
evidence-based extrapolation for biosimilars
-
35:31
understanding biosimilars: how the availability of biosimilars will impact clinical practice
-
8:10
module 6: biosimilars—advances in research and development
-
0:50
introduction: biosimilars—advances in research and development
-
2:46
interchangeability 101 - biosimilars & interchangeable biologics
-
2:43
biosimilar interchangeability
-
1:21
biosimilars: terms to know
-
5:07
biosimilar interchangeability in practice
-
2:21
what are biosimilars?
-
4:02
healthcare asks: what are biosimilars?
-
50:28
biosimilars and the oncology pcsp: value-based strategies to improve access and reduce cost
-
1:28
fast facts about the quality of biosimilars – amgen science